株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

風疹:パイプライン製品の分析

Rubella (German Measles) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 271825
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.19円で換算しております。
Back to Top
風疹:パイプライン製品の分析 Rubella (German Measles) - Pipeline Review, H2 2017
出版日: 2017年11月14日 ページ情報: 英文 33 Pages
概要

風疹は、三日ばしかとしても知られる、急性の接触伝染性ウイルス感染症です。風疹ウイルスは、感染者のくしゃみや咳の飛沫によって伝染します。発熱、頭痛、鼻づまりや鼻水、炎症、眼の充血、関節痛、頭蓋底・頸背部・耳介後部のリンパ節腫大などの症状があります。

当レポートでは、風疹に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

風疹の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

風疹:治療薬の評価

  • 投与経路別
  • 分子タイプ別

風疹の治療薬開発に従事している企業

  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • 第一三共
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Prometheon Pharma LLC
  • Sinovac Biotech Ltd
  • Zydus Cadila Healthcare Ltd

薬剤プロファイル

風疹:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9903IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) - Pipeline Review, H2 2017, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 1, 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Rubella (German Measles) - Overview 6
  • Rubella (German Measles) - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Pipeline by Universities/Institutes 9
  • Products under Development by Companies 10
  • Products under Development by Universities/Institutes 11
  • Rubella (German Measles) - Therapeutics Assessment 12
  • Assessment by Route of Administration 12
  • Assessment by Molecule Type 14
  • Rubella (German Measles) - Companies Involved in Therapeutics Development 16
  • Beijing Minhai Biotechnology Co Ltd 16
  • Biological E Ltd 16
  • Cadila Healthcare Ltd 16
  • Daiichi Sankyo Co Ltd 17
  • GlaxoSmithKline Plc 17
  • Indian Immunologicals Ltd 18
  • Sinovac Biotech Ltd 18
  • Rubella (German Measles) - Drug Profiles 19
  • (measles + mumps + rubella + varicella) vaccine - Drug Profile 19
  • Product Description 19
  • Mechanism Of Action 19
  • R&D Progress 19
  • (measles + mumps + rubella) vaccine - Drug Profile 20
  • Product Description 20
  • Mechanism Of Action 20
  • R&D Progress 20
  • (measles + mumps + rubella) vaccine - Drug Profile 21
  • Product Description 21
  • Mechanism Of Action 21
  • R&D Progress 21
  • (measles + mumps + rubella) vaccine - Drug Profile 22
  • Product Description 22
  • Mechanism Of Action 22
  • R&D Progress 22
  • (measles + rubella + varicella) vaccine - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • (measles + rubella) vaccine - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • (measles + rubella) vaccine - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • (measles + rubella) vaccine - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • (measles + rubella) vaccine - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • rubella vaccine - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • VN-0102 - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • Rubella (German Measles) - Dormant Projects 31
  • Appendix 32
  • Methodology 32
  • Coverage 32
  • Secondary Research 32
  • Primary Research 32
  • Expert Panel Validation 32
  • Contact Us 32
  • Disclaimer 33

List of Tables

  • Number of Products under Development for Rubella (German Measles), H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products under Development by Universities/Institutes, H2 2017 9
  • Products under Development by Companies, H2 2017 10
  • Products under Development by Universities/Institutes, H2 2017 11
  • Number of Products by Stage and Route of Administration, H2 2017 13
  • Number of Products by Stage and Molecule Type, H2 2017 15
  • Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017 16
  • Rubella (German Measles) - Pipeline by Biological E Ltd, H2 2017 16
  • Rubella (German Measles) - Pipeline by Cadila Healthcare Ltd, H2 2017 17
  • Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 17
  • Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H2 2017 18
  • Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, H2 2017 18
  • Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, H2 2017 18
  • Rubella (German Measles) - Dormant Projects, H2 2017 31

List of Figures

  • Number of Products under Development for Rubella (German Measles), H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products by Routes of Administration, H2 2017 12
  • Number of Products by Stage and Routes of Administration, H2 2017 12
  • Number of Products by Molecule Types, H2 2017 14
  • Number of Products by Stage and Molecule Types, H2 2017 14
Back to Top